Applications

- Treatment and/or prevention of Alzheimer’s Disease
- Applicable to other neurodegenerative disorders

Advantages

- Improved pharmacokinetic properties
- Reduced toxic side effects
- Reduced cost
- Improved patient compliance
- Enhanced potency

Market Need

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder and the leading cause of dementia. Currently, treatments exist only to alleviate symptoms and increase quality of life for patients with AD like symptoms. Unfortunately there is still a great need to find a cure and preventative treatment. The main challenge in AD treatment is the presence of multiple targets for drug delivery.

Technology Summary

Dr. Shijun Zhang has designed and synthesized a series of hybrid compounds of curcumin and melatonin as potential treatment and/or preventative agent for neurodegenerative disorders including Alzheimer's disease. These hybrid compounds were developed to specifically inhibit Aβ oligomerization/aggregation, which leads to decreased synaptic plasticity and increased apoptosis as observed in AD. In vivo studies using a neuroblastoma cell line (that expresses Aβ aggregates leading to cell death) showed that these hybrid compounds exhibited increased neuroprotection and cell survival. Compared to other forms of treatment, these hybrid compounds show enhanced potency, improved pharmacokinetic properties and reduced toxic side effects.

Technology Status

In vitro data available
Patent pending: U.S. and foreign rights available
This technology is available for licensing to industry for further development and commercialization.

Inventors

Shijun Zhang, Ph.D.

Contact

Magdalena K. Morgan, Ph.D.
Licensing Associate
mkmorgan@vcu.edu
Direct 804-827-6095

Neuroprotection potency of Formula III on MC65 cells in the presence of tetracycline (TC).

Antioxidant effects of Formula III on MC65 cells.